S Sethi

Summary

Country: USA

Publications

  1. ncbi Bacterial infection and the pathogenesis of COPD
    S Sethi
    VA Western New York Healthcare System and Department of Medicine, Division of Pulmonary and Critical Care, State University of New York at Buffalo, Buffalo, NY 14215, USA
    Chest 117:286S-91S. 2000
  2. ncbi Infectious etiology of acute exacerbations of chronic bronchitis
    S Sethi
    Department of Medicine, Division of Pulmonary and Critical Care Medicine, State University of New York at Buffalo and Department of Veterans Affairs Western New York Healthcare System, Buffalo, NY 14215, USA
    Chest 117:380S-5S. 2000
  3. ncbi Simultaneous respiratory tract colonization by multiple strains of nontypeable haemophilus influenzae in chronic obstructive pulmonary disease: implications for antibiotic therapy
    T F Murphy
    Division of Infectious Diseases, Department of Microbiology, State University of New York at Buffalo, USA
    J Infect Dis 180:404-9. 1999
  4. ncbi Acute exacerbations of chronic bronchitis: what role for the new fluoroquinolones?
    A Obaji
    Division of Pulmonary and Critical Care Medicine, State University of New York at Buffalo, USA
    Drugs Aging 18:1-11. 2001
  5. ncbi Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents
    M S Niederman
    Department of Medicine, Winthrop University Hospital, 222 Station Plaza North, Suite 509, Mineola, NY 11501, USA
    Respir Med 100:1781-90. 2006
  6. ncbi Analysis of antigenic structure and human immune response to outer membrane protein CD of Moraxella catarrhalis
    T F Murphy
    Divisions of Infectious Diseases, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, New York 14215, USA
    Infect Immun 67:4578-85. 1999
  7. ncbi Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review
    S Sethi
    Division of Pulmonary and Critical Medicine, State University of New York at Buffalo, Buffalo, New York, USA
    Clin Microbiol Rev 14:336-63. 2001
  8. ncbi A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis
    S Sethi
    Pulmonary and Critical Care Medicine, University at Buffalo, State University of New York, Buffalo, NY, USA
    Respir Med 98:697-707. 2004

Detail Information

Publications8

  1. ncbi Bacterial infection and the pathogenesis of COPD
    S Sethi
    VA Western New York Healthcare System and Department of Medicine, Division of Pulmonary and Critical Care, State University of New York at Buffalo, Buffalo, NY 14215, USA
    Chest 117:286S-91S. 2000
    ..Application of newer molecular and immunologic research techniques is helping us define precisely the role of bacterial infection in COPD...
  2. ncbi Infectious etiology of acute exacerbations of chronic bronchitis
    S Sethi
    Department of Medicine, Division of Pulmonary and Critical Care Medicine, State University of New York at Buffalo and Department of Veterans Affairs Western New York Healthcare System, Buffalo, NY 14215, USA
    Chest 117:380S-5S. 2000
    ..Emerging evidence from molecular epidemiology and measurement of airway inflammation further support the role of bacteria in AECB. When properly defined, 80% of AECB are likely to be infectious in origin...
  3. ncbi Simultaneous respiratory tract colonization by multiple strains of nontypeable haemophilus influenzae in chronic obstructive pulmonary disease: implications for antibiotic therapy
    T F Murphy
    Division of Infectious Diseases, Department of Microbiology, State University of New York at Buffalo, USA
    J Infect Dis 180:404-9. 1999
    ..Therefore, multiple strains of H. influenzae are frequently present simultaneously in the sputum of adults with COPD, and the antimicrobial susceptibility of different strains in the same sputum sometimes differs...
  4. ncbi Acute exacerbations of chronic bronchitis: what role for the new fluoroquinolones?
    A Obaji
    Division of Pulmonary and Critical Care Medicine, State University of New York at Buffalo, USA
    Drugs Aging 18:1-11. 2001
    ..Such selected use of the new fluoroquinolones balances individual benefit with societal concerns of the use of these agents for AECB...
  5. ncbi Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents
    M S Niederman
    Department of Medicine, Winthrop University Hospital, 222 Station Plaza North, Suite 509, Mineola, NY 11501, USA
    Respir Med 100:1781-90. 2006
    ..278); similar results were found when moxifloxacin was compared individually with each macrolide. For patients with AECB due to H. influenzae, moxifloxacin provided superior bacterial eradication rates than macrolide therapy...
  6. ncbi Analysis of antigenic structure and human immune response to outer membrane protein CD of Moraxella catarrhalis
    T F Murphy
    Divisions of Infectious Diseases, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, New York 14215, USA
    Infect Immun 67:4578-85. 1999
    ..While individual adults with COPD show variability in the immune response to OMP CD, a specific region of the OMP CD molecule (amino acids 203 to 260) is important as a target of the human immune response...
  7. ncbi Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review
    S Sethi
    Division of Pulmonary and Critical Medicine, State University of New York at Buffalo, Buffalo, New York, USA
    Clin Microbiol Rev 14:336-63. 2001
    ....
  8. ncbi A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis
    S Sethi
    Pulmonary and Critical Care Medicine, University at Buffalo, State University of New York, Buffalo, NY, USA
    Respir Med 98:697-707. 2004
    ..To demonstrate that 5 days of treatment with a new fluoroquinolone, gemifloxacin, is at least as effective as 7 days of treatment with levofloxacin in adult patients with acute exacerbation of chronic bronchitis (AECB)...